Ciprofloxacin hydrochloride, a broad-spectrum antibiotic with bactericidal activity againstCiprofloxacin (ciprofloxacin) hydrochloride, is an effective combination therapy for bacterial infections. This article reviews the history and current status of the drug and includes references to studies and clinical trials. It also outlines its mechanism of action and its clinical application.
Ciprofloxacin hydrochloride is used in the management of:
The active ingredient in Ciprofloxacin hydrochloride is ciprofloxacin hydrochloride, which is an antibiotic with bactericidal activity.
The2023Clinical Research Program of the College of Pharmacy at Northwestern University has shown that approximately90%of patients with bacterial infections are diagnosed with a positive test forCiprofloxacin (ciprofloxacin hydrochloride) by polymerase chain reaction (PCR)Other studies have shown that this test may be effective for most patients.
However, the30%increasedCiprofloxacindoi/10.3390/crp.302024
is not specific for the treatment of UTIs.
The incidence of adverse effects forCiprofloxacin (ciprofloxacin hydrochloride) is low (1.2-2.3%). These effects may include:
Ciprofloxacin hydrochloride may cause serious side effects including:
The following are contraindicated in the treatment of ciprofloxacin hydrochloride infection.
Product
Ciprofloxacin
Product Information
Ciprofloxacin is a quinolone antibiotic used to treat a wide variety of bacterial infections. Ciprofloxacin is effective against a wide range of Gram-positive and Gram-negative bacteria, including Staphylococcus aureus, Streptococcus, E. coli, Bacteroides, and Haemophilus influenzae. The antibiotic targets bacteria, preventing their destruction by the body's immune system. It is often prescribed for conditions such as skin infections, urinary tract infections, and respiratory tract infections. This medication can be effective against bacterial infections, such as those caused by Staphylococcus aureus, Streptococcus aureus, and Haemophilus influenzae.
Dosage and Administration
Ciprofloxacin should be taken orally, with or without food. It is usually recommended to take Ciprofloxacin at evenly spaced intervals as per the dosing schedule prescribed by your healthcare provider. Ciprofloxacin may take several days to usually clear up. However, clear-up time is the time it takes the bacteria to survive. If the infection is persistent, contact your healthcare provider.
Precautions
Before using Ciprofloxacin, inform your healthcare provider if you are allergic to it, or if you have any other allergies. Ciprofloxacin can cause an allergic reaction if any of the following apply to you: you have asthma, including hives; you have allergies to penicillin or cephalosporin antibiotics, including cephalosporin antibiotics, toenems (e.g. cephalosporins such as ceftriaxone); you have liver problems; you have ever had a serious allergic reaction (such as wheezing, tightness in the chest, a fast heartbeat, or other allergic states) to penicillin or cephalosporin antibiotics; you have kidney problems; you are a woman; you are taking any medications, including blood thinners, anticoagulants, or antidepressants)If you have an allergy to cephalosporin antibiotics, including cephalosporins, or any other drugs that treat or prevent infection; you have a stomach or intestinal ulcer; you are taking any other medicines, including those that treat bacterial infections, to ensure that Ciprofloxacin is effective against them. Before using Ciprofloxacin, inform your healthcare provider about any other health conditions or medications you are currently taking. This includes prescription or nonprescription medicines, vitamins, minerals, or herbal products. Ciprofloxacin may cause side effects, including diarrhea, nausea, and vomiting. Some common side effects may include: diarrhea, nausea, vomiting, abdominal pain, and stomach pain. More serious side effects, such as allergic reactions (rash, itchiness, breathing difficulty, or swelling of the face or throat), fluid retention, changes in color vision, or difficulty breathing may occur. If you experience signs of a serious allergic reaction, such as hives, difficulty breathing, swelling of the face or throat or difficulty swallowing, call your healthcare provider or get medical attention at once. Ciprofloxacin may cause a hypersensitivity reaction in some people. Contact your healthcare provider at once if you have severe or persistent skin or breathing problems, especially if you are breastfeeding. Contact your healthcare provider at once if you experience severe skin reactions, including skin rash, blistering of the skin, peeling of the skin, or a skin rash that doesn't stop. Serious skin reactions such as rashes, blisters, or peeling of the skin (difficulty breathing or swallowing, swelling of the face or throat or skin rash with no protection from light or heat, especially if they get worse), fever and/or skin rash that doesn't stop, that occur even when you are not having medical procedures, are more likely to happen if you are taking Ciprofloxacin, especially if they occur at times when other medicines are not being taken. Ciprofloxacin may cause other effects, such as increased sensitivity to sunlight, sunburn, or increased sensitivity to sunlight to your skin's own skin's own bacteria. This could lead to sunburn or sun rash in areas of the skin that are more sensitive to sunlight (such as the eyes), especially at high altitudes. Sunburns that last more than a few days and are bloody can also occur at high altitudes, so it is best to avoid swimming in the far-flung's skin.
Waldinger B, Burch M, Kocsis O, DeSalle F, et al. Clinical practice guidelines for the management of post-traumatic corneal ulcers. J Ophthalmol. 2002;49(5):e907–10.
Al-Muny A, Ayozaki A, Koyama K, Maki E, et al. The use of ciprofloxacin ophthalmic solution for the treatment of post-traumatic corneal ulcers. Int J Ophthalmol. 2005;20(3):213–21.
Al-Muny A, Yashdy A, Al-Shiry A, Shirkov R, et al. Use of ciprofloxacin ophthalmic solution in the treatment of post-traumatic corneal ulcers: a double-blind randomized, placebo-controlled trial. 2007;28(5):e13–16.
Al-Shiry A, Oka H. Ciprofloxacin ophthalmic solution: a new approach to the treatment of post-traumatic corneal ulcers. Ophthalmology. 2008;52(2):79–84.
Al-Shiry A, Shirkov R, Kocsis O, Maki E, et al. Use of ciprofloxacin ophthalmic solution for the treatment of post-traumatic corneal ulcers. Eur Ophthalmol. 2012;11(9):979–81.
Alioum B, Al-Shiry A, Yashdy A, Yashdy O, et al. Effect of the use of ciprofloxacin ophthalmic solution on the improvement of corneal thickness in post-traumatic corneal ulcers. 2005;20(3):219–22.
Al-Shiry A, Al-Shiry A, Al-Yawyin M, Al-Bukhi S, et al. Effect of the use of ciprofloxacin ophthalmic solution on the improvement of corneal thickness. 2005;20(3):224–30.
Ciprofloxacin ophthalmic solution significantly improves corneal thickness in patients with post-traumatic corneal ulcers. 2007;28(2):119–26.
Al-Yawyin M, Koyama K, Yashdy A. Effect of ciprofloxacin ophthalmic solution on corneal thickness. 2008;29(5):e5–9.
Al-Bukhi S, Maki E, Yashdy A. 2010;31(2):119–27.
Al-Shiry A, Shirkov R, Kocsis O, Yashdy A. A comparative study of ciprofloxacin ophthalmic solution and topical ointment for the treatment of post-traumatic corneal ulcers. 2012;34(1):21–5.
Al-Yawyin M, Maki E, Yashdy A. Ciprofloxacin ophthalmic solution is better than topical ointment for the treatment of post-traumatic corneal ulcers. 2012;34(3):224–30.
Alioum B, Al-Shiry A, Yashdy A.
Nathalyan M, Kalyan S, et al. The pharmacokinetics of ciprofloxacin in healthy volunteers. Ann Pharmacother. 2000; 16:12–19.
Baron S, Mocke N, et al. Effect of ciprofloxacin on ciprofloxacin absorption after oral administration. J Clin Pharmacol. 2004; 21:1688–93.
Nathalyan S, Mocke N, et al. Effect of ciprofloxacin on the pharmacokinetics of levofloxacin in healthy volunteers. 2004; 21:1527–35.
Kalyan S, Dokshak R, et al. The pharmacokinetics of ciprofloxacin in healthy volunteers: a comparative study. 2004; 21:1713–23.
Wang M, Zhang X, et al. Ciprofloxacin and other fluoroquinolones: a review of their pharmacokinetic properties and clinical use. 2004; 21:2371–83.
Baron S, Kalyan S, et al. 2004; 21:1681–94.
Nathalyan S, Kalyan S, et al.
Kalyan S, et al. Ciprofloxacin and fluoroquinolone: a review of their pharmacokinetics and clinical use. 2004; 21:1727–35.
Ciprofloxacin and fluoroquinolones: a review of their pharmacokinetics and clinical use.
Nathalyan S, et al. Ciprofloxacin: a review of its pharmacokinetics and clinical use.
Zhou L, Wu J, et al. A comparative study of ciprofloxacin (Cipro) with fluoroquinolone (Flu) in the treatment of urinary retention. 2004; 21:2121–9.
A comparative study of ciprofloxacin with fluoroquinolone (Flu) in the treatment of urinary retention.
Wu Y, Wang W, et al.
Effect of ciprofloxacin on the pharmacokinetics of levofloxacin.
Wu Y, et al.
A CIPRO(R) trial of a new antibiotic in a severe form of pneumonia was halted on April 22, 2010, when the US Food and Drug Administration (FDA) did not approve the use of ciprofloxacin in patients with pneumonia and severe exacerbation of chronic bronchitis, in view of the significant impact that it could have on treatment decisions. The FDA, in its decision, found that the drug had been approved by the agency in 1996, for the treatment of pneumonia. The drug was approved to treat moderate and severe pneumonia in children, adults, and children below the age of eight. The agency also approved the treatment of moderate and severe exacerbation of chronic bronchitis, which causes bronchospasm in children, and severe acute exacerbation of COPD, which causes bronchospasm in adults. Ciprofloxacin was first approved in the US in 1987. The US was the first indication for the drug to be approved for the treatment of acute respiratory failure in patients with acute bacterial exacerbation of chronic bronchitis (A-uffs) in 1989. In 2001, a similar drug, ciprofloxacin-dipyridazine (CBD) was approved for treatment of pneumonia. The FDA also approved the treatment of severe acute exacerbation of COPD in patients with severe acute bacterial exacerbation of chronic bronchitis (S-uffs).
In this case, the FDA concluded that the benefits of the drug for treating pneumonia, acute exacerbation of COPD, and acute bacterial exacerbation of chronic bronchitis were not sufficient to warrant use of the drug in patients with A-uffs. The FDA also noted that the drug’s efficacy was similar to that of a drug used for acute exacerbation of chronic bronchitis and that ciprofloxacin was not approved for use in patients with severe acute bacterial exacerbation of COPD.
The US FDA issued a decision on November 15, 2010. The FDA decision was published in theJournal of Clinical Infectious Diseases.A CIPRO(R) trial of a new antibiotic in severe form of pneumonia was halted on April 22, 2010, when the US Food and Drug Administration (FDA) did not approve the use of ciprofloxacin in patients with pneumonia and severe exacerbation of chronic bronchitis, in view of the significant impact that it could have on treatment decisions. The FDA also approved the treatment of moderate and severe exacerbation of COPD, which causes bronchospasm in children, and severe acute exacerbation of COPD, which causes bronchospasm in adults. The FDA also approved the treatment of severe acute exacerbation of COPD, which causes bronchospasm in adults.The US FDA issued a decision on March 6, 2010. The US FDA published a decision on April 27, 2010. The US FDA published a decision on July 2, 2010. The US FDA published a decision on July 3, 2010. The US FDA published a decision on November 15, 2010. The US FDA published a decision on August 4, 2010. The US FDA published a decision on May 7, 2010. The US FDA published a decision on June 3, 2010. The US FDA published a decision on December 5, 2010.
Stade de France Pharmacy